Ipsen (Euronext: IPN; ADR: IPSEY) today announced that irinotecan liposome injection (Onivyde®), cabozantinib (Cabometyx®), lanreotide (Somatuline® Autogel® / Depot), telotristat ethyl (Xermelo®) and neuroendocrine tumors are the subject of 16 presentations at the European Society of Medical Oncology (ESMO 2017) congress. The meeting takes place in Madrid (Spain) September 8-12, 2017.
